Fgen stock: berger montague investigates potential securities fraud claims against fibrogen, inc. (fgen) for manipulating drug data

Philadelphia, pennsylvania--(newsfile corp. - april 8, 2021) - berger montague is investigating potential securities fraud claims against fibrogen, inc. ("fibrogen" or the "company") on behalf of investors who purchased fibrogen securities (nasdaq: fgen). if you purchased fibrogen securities, have questions concerning your rights or interests, or would like to discuss berger montague's investigation, please contact attorneys andrew abramowitz at aabramowitz@bm.net or (215) 875-3015, or donnell much at dmuch@bm.net or (215) 875-4667, or contact us at...
FGEN Ratings Summary
FGEN Quant Ranking